Literature DB >> 11586556

Clostridium difficile.

L Kyne1, R J Farrell, C P Kelly.   

Abstract

Clostridium difficile is a major cause of antibiotic-associated diarrhea and colitis. The incidence of infection with this organism is increasing in hospitals worldwide, consequent to the widespread use of broad-spectrum antibiotics. Pathogenic strains of C. difficile produce two protein exotoxins, toxin A and toxin B, that cause colonic mucosal injury and inflammation. Many patients who are colonized are asymptomatic, and recent evidence indicates that diarrhea and colitis occur in those individuals who lack a protective antitoxin immune response. In patients who do develop symptoms, the spectrum of C. difficile disease ranges from mild diarrhea to fulminant pseudomembranous colitis. Prevention of nosocomial C. difficile infection involves judicious use of antibiotics and multidisciplinary infection control measures to reduce environmental contamination and patient cross-infection. Ultimately, active or passive immunization against C. difficile may be an effective means of controlling the growing problem of nosocomial C. difficile diarrhea and colitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586556     DOI: 10.1016/s0889-8553(05)70209-0

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  29 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Pathology of drug-associated gastrointestinal disease.

Authors:  Ashley B Price
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

3.  Fulminant Clostridium difficile colitis in a post-liver transplant patient.

Authors:  Maximilian Lee; Andrew A Shelton; Waldo L Concepcion; Clark A Bonham; Tami J Daugherty
Journal:  Dig Dis Sci       Date:  2010-07-16       Impact factor: 3.199

4.  Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid.

Authors:  T Norén; M Wullt; Thomas Akerlund; E Bäck; I Odenholt; L G Burman
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 5.  Review: Clostridium difficile-associated disorders/diarrhea and Clostridium difficile colitis: the emergence of a more virulent era.

Authors:  Perry Hookman; Jamie S Barkin
Journal:  Dig Dis Sci       Date:  2007-02-16       Impact factor: 3.199

Review 6.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 7.  Clostridium difficile-associated colitis.

Authors:  Mark W Hull; Paul L Beck
Journal:  Can Fam Physician       Date:  2004-11       Impact factor: 3.275

8.  Ulcerative proctitis.

Authors:  Charles B Whitlow
Journal:  Clin Colon Rectal Surg       Date:  2004-02

9.  Rifalazil treats and prevents relapse of clostridium difficile-associated diarrhea in hamsters.

Authors:  Pauline M Anton; Michael O'Brien; Efi Kokkotou; Barry Eisenstein; Arthur Michaelis; David Rothstein; Sophia Paraschos; Ciáran P Kelly; Charalabos Pothoulakis
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Clostridium difficile-associated disease in allogeneic hematopoietic stem-cell transplant recipients: risk associations, protective associations, and outcomes.

Authors:  Erik R Dubberke; Kimberlay A Reske; Anand Srivastava; Justin Sadhu; Robert Gatti; Rebecca M Young; Lauren C Rakes; Brian Dieckgraefe; John DiPersio; Victoria J Fraser
Journal:  Clin Transplant       Date:  2009-07-13       Impact factor: 2.863

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.